Združeni arabski emirati - angleščina - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

pharmatrade united states of america - 10 single-dose pre-filled syringes (0.7 ml) - injection - 60 µg/60 µg/60 µg/60 µg/pre-filled syringe - immunologicals , vaccines-vaccines , antisera

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 7.5ug (a/michigan/45/2015, x-275); influenza virus a/singapore/infimh-16-0019/2016 (h3n2) - like strain 7.5ug (a/singapore/infimh-16-0019/2016, nib-104); influenza virus b/brisbane/60/2008 - like strain 7.5ug (b/brisbane/60/2008 (victoria lineage)); influenza virus b/phuket/3073/2013 - like strain 7.5ug (b/phuket/3073/2013 (yamagata lineage)) - suspension for injection - 30 mcg - active: influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 7.5ug (a/michigan/45/2015, x-275) influenza virus a/singapore/infimh-16-0019/2016 (h3n2) - like strain 7.5ug (a/singapore/infimh-16-0019/2016, nib-104) influenza virus b/brisbane/60/2008 - like strain 7.5ug (b/brisbane/60/2008 (victoria lineage)) influenza virus b/phuket/3073/2013 - like strain 7.5ug (b/phuket/3073/2013 (yamagata lineage)) excipient: octoxinol 9 phosphate buffered saline - fluquadri junior is indicated for active immunisation of influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine. fluquadri junior is indicated for use in children aged 6 months to 35 months inclusive.

Avstralija - angleščina - APVMA (Australian Pesticides and Veterinary Medicines Authority)

arysta lifescience benelux sprl - propamocarb present as monohydrochloride - aqueous concentrate - propamocarb present as monohydrochloride carbamate-methylcarbamate active 605.0 g/l - fungicide - adiantum - pot plant | aechmea spp. - cuttings | aechmea spp. - pot plant | aechmea spp. - pricking-off seedling | aechmea spp. - wilt rootrot or damping off | damping-off | pythium root rot | pythium soil fungus | seedling root rot | soil fungi

Kanada - angleščina - Health Canada

fresenius kabi canada ltd - amiodarone hydrochloride - solution - 50mg - amiodarone hydrochloride 50mg - class iii antiarrythmics

Kanada - angleščina - Health Canada

fresenius kabi canada ltd - pamidronate disodium - solution - 3mg - pamidronate disodium 3mg - bone resorption inhibitors

Kanada - angleščina - Health Canada

fresenius kabi canada ltd - pamidronate disodium - solution - 6mg - pamidronate disodium 6mg - bone resorption inhibitors

Kanada - angleščina - Health Canada

fresenius kabi canada ltd - pamidronate disodium - solution - 9mg - pamidronate disodium 9mg - bone resorption inhibitors

Združene države Amerike - angleščina - NLM (National Library of Medicine)

protein sciences corporation - influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen (unii: 1se9z7d2qr) (influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen - unii:1se9z7d2qr), influenza a virus a/texas/50/2012 (h3n2) recombinant hemagglutinin antigen (unii: 1iqz1wce3y) (influenza a virus a/texas/50/2012 (h3n2) recombinant hemagglutinin antigen - unii:1iqz1wce3y), influenza b virus b/massachusetts/2/2012 recombinant hemagglutinin antigen (unii: ayr0wzx7jh) (influenza b virus b/massachus - flublok is a vaccine indicated for active immunization against disease caused by influenza virus subtypes a and type b contained in the vaccine. flublok is approved for use in persons 18 years of age and older. in persons 18 through 49 years of age, this indication is based on a controlled clinical study demonstrating a decrease in influenza disease after vaccination with flublok. in persons 50 years of age and older, this indication is based on the immune response elicited by flublok; data demonstrating a decrease in influenza disease in persons 50 years and older after vaccination with flublok are not available. (see clinical studies [ 14]) flublok is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine (see description [11] and postmarketing experience [6.2]). reproduction studies have been performed in rats at a dose approximately 300 times the human dose (on a mg/kg basis) and have revealed no evidence of impaired fertility or harm to

Združene države Amerike - angleščina - NLM (National Library of Medicine)

protein sciences corporation - influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen (unii: 1se9z7d2qr) (influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen - unii:1se9z7d2qr), influenza a virus a/switzerland/9715293/2013 (h3n2) recombinant hemagglutinin antigen (unii: d2053d6yqu) (influenza a virus a/switzerland/9715293/2013 (h3n2) recombinant hemagglutinin antigen - unii:d2053d6yqu), influenza b virus b/phuket/3073/2013 recombinant hemagglutinin antigen (unii: poq8dqo9s3) (influenza b - flublok is a vaccine indicated for active immunization against disease caused by influenza virus subtypes a and type b contained in the vaccine. flublok is approved for use in persons 18 years of age and older. in persons 18 through 49 years of age, this indication is based on a controlled clinical study demonstrating a decrease in influenza disease after vaccination with flublok. in persons 50 years of age and older, this indication is based on the immune response elicited by flublok; data demonstrating a decrease in influenza disease in persons 50 years and older after vaccination with flublok are not available. (see clinical studies [ 14] ) flublok is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine (see description [11] and postmarketing experience [6.2] ). reproduction studies have been performed in rats at a dose approximately 300 times the human dose (on a mg/kg basis) and have revealed no evidence of impaired fertility or harm t

Združene države Amerike - angleščina - NLM (National Library of Medicine)

protein sciences corporation - influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen (unii: 1se9z7d2qr) (influenza a virus a/california/7/2009 (h1n1) recombinant hemagglutinin antigen - unii:1se9z7d2qr), influenza a virus a/hong kong/4801/2014 (h3n2) recombinant hemagglutinin antigen (unii: 2i1eol437m) (influenza a virus a/hong kong/4801/2014 (h3n2) recombinant hemagglutinin antigen - unii:2i1eol437m), influenza b virus b/brisbane/60/2008 recombinant hemagglutinin antigen (unii: 058u2312cr) (influenza b virus b/b - flublok is a vaccine indicated for active immunization against disease caused by influenza virus subtypes a and type b contained in the vaccine. flublok is approved for use in persons 18 years of age and older. in persons 18 through 49 years of age, this indication is based on a controlled clinical study demonstrating a decrease in influenza disease after vaccination with flublok. in persons 50 years of age and older, this indication is based on the immune response elicited by flublok; data demonstrating a decrease in influenza disease in persons 50 years and older after vaccination with flublok are not available. (see clinical studies [ 14] ) flublok is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine (see description [11] and postmarketing experience [6.2] ). reproduction studies have been performed in rats at a dose approximately 300 times the human dose (on a mg/kg basis) and have revealed no evidence of impaired fertility or harm t